# The role of novel oncogenic histone H3 lysine variants in defining a therapeutically actionable epigenetic signature

> **NIH NIH R21** · EMORY UNIVERSITY · 2022 · $210,524

## Abstract

PROJECT SUMMARY/ABSTRACT
 Over 1.7 million individuals will be diagnosed with cancer and 600,000 cancer-associated deaths will occur
in the US in 2020. Devoting resources to develop tools and reagents to define mechanisms of oncogenicity and
applying this knowledge to the development of therapeutic agents and diagnostic tools is clearly required to
improve patient outcome. Recent research has identified cancer-associated amino acid substitutions that occur
in the evolutionarily conserved histone proteins, leading to the term “oncohistones.” Examples of such changes
linked to cancer include H3K27M, H3G34V/R/D, and H3K36M. While the mechanism of oncogenicity for these
mutations varies, each amino acid change perturbs the histone methylation landscape, affecting transcriptional
regulation. Understanding how oncohistones alter gene expression can provide critical therapeutic insight.
Changes to the histone methylation landscape in H3K27M-expressing gliomas result in dopamine receptor D2
(DRD2) overexpression and these tumors respond to the DRD2 and/or CLPP antagonist ONC201. This example
highlights how cancer-associated epigenetic changes can unmask potentially druggable targets.
 In our preliminary studies, we have identified a series of dominant H3 mutations, termed X to K (R42K,
E50K, Q68K, E73K), in which the wildtype amino acid is changed to a lysine, in more than 30 patient tumors in
breast and other cancers. Preliminary in vitro experiments suggest that X to K mutation promotes transformation;
a major indicator that H3 X to K mutations produce bona-fide oncohistones. However, both how these X to K
amino acid changes alter the function of these histones and the mechanism(s) by which X to K oncohistones
produce oncogenic phenotypes is unclear. We hypothesize that H3 X to K changes confer oncogenic
properties by (1) introducing localized structural changes that alter nucleosome integrity and/or function
and/or (2) introducing a new substrate for chromatin modifiers, thereby supporting a novel, and
potentially targetable, gene expression program. Drawing on the integrated environment at Emory/Winship,
we propose a collaborative multi-PI approach to test our hypothesis through the following aims: Aim 1) Examine
the impact of H3 X to K amino acid changes on histone function together with cell and tumor growth; and Aim 2)
Define how X to K amino acid changes in histones alter gene expression. Importantly, the proposed studies lay
the groundwork for defining both new cancer signatures and druggable targets. Our interdisciplinary team is
uniquely qualified to perform the proposed preclinical studies, which are directly related to advancements in
cancer treatment and diagnosis. The long-term goal of our studies is to develop diagnostic tools for the detection
of oncohistone-associated tumors and identify a therapeutically actionable epigenetic signature in patient tumors
characterized by these H3 X to K oncogenic mutations.

## Key facts

- **NIH application ID:** 10436987
- **Project number:** 5R21CA256456-02
- **Recipient organization:** EMORY UNIVERSITY
- **Principal Investigator:** ANITA H. CORBETT
- **Activity code:** R21 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $210,524
- **Award type:** 5
- **Project period:** 2021-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10436987

## Citation

> US National Institutes of Health, RePORTER application 10436987, The role of novel oncogenic histone H3 lysine variants in defining a therapeutically actionable epigenetic signature (5R21CA256456-02). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10436987. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*